The role of glutamate in diabetic and in chemotherapy induced peripheral neuropathies and its regulation by glutamate carboxypeptidase II

• Published in: Current medicinal chemistry Vol. 19; no. 9; p. 1261
• Main Authors: Carozzi, V A, Ceresa, C
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01-03-2012
• Subjects: Animals; Antineoplastic Agents - adverse effects; Diabetic Neuropathies - drug therapy; Diabetic Neuropathies - enzymology; Diabetic Neuropathies - metabolism; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors - pharmacology; Enzyme Inhibitors - therapeutic use; Glutamate Carboxypeptidase II - antagonists & inhibitors; Glutamate Carboxypeptidase II - metabolism; Glutamic Acid - metabolism; Humans; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; Peripheral Nervous System - drug effects; Peripheral Nervous System - enzymology; Peripheral Nervous System - metabolism; Peripheral Nervous System Diseases - chemically induced; Peripheral Nervous System Diseases - drug therapy; Peripheral Nervous System Diseases - enzymology; Peripheral Nervous System Diseases - metabolism
• ISSN: 1875-533X
• DOI: 10.2174/092986712799462694

Glutamate has been implicated in the pathogenesis of several diseases on the central nervous system, but recent studies have also suggested that it can be involved also in the onset and course of peripheral neuropathies. Given the increasing evidence of this possibility, several attempts have been performed in order to modulate its activity. Among them, glutamate carboxypeptidase II (GCP II) inhibition demonstrated promising results in different models of peripheral nerve damage, including diabetic and toxic neuropathies.